Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Locoregional therapy plus toripalimab in hepatocellular carcinoma after first-line progression
ChiCTR2500114618Phase 2Not yet recruiting
- Sponsor
- Yantai Yuhuangding Hospital
- Start
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in hepatocellular carcinoma (HCC), sponsored by Yantai Yuhuangding Hospital. Primary endpoint: Objective response rate (ORR). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500114618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114618.